Pacira Pharmaceuticals Inc. provided revenue guidance for the fourth quarter and full year 2015. For the quarter, the company has reported that its unaudited revenue estimates for EXPAREL were $67.2 million, an increase of 13% compared with sales of $59.7 million for third quarter of 2015. 

For the full year, the company's EXPAREL sales were an estimated $239.9 million, an increase of 27% compared with $188.5 million in 2014.